Pinealon
Overview
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed as part of the Khavinson peptide bioregulator series, designed to mimic endogenous short peptides that regulate gene expression in neural tissues. It is hypothesized to interact with chromatin and influence transcription of genes involved in neuronal survival and plasticity. Pinealon has been studied primarily in the context of age-related cognitive decline and neurodegenerative models.
Key Research Findings
Preclinical studies in rodent models of aging and neurodegeneration have reported improvements in memory, motor coordination, and markers of neuronal health, with data appearing in Russian pharmacology journals. Human clinical evidence remains sparse, with small observational studies suggesting subjective cognitive benefit in elderly populations. Peer-reviewed replication and placebo-controlled trials in international journals are lacking.
Subcutaneous injection, Oral
Investigational
Interested in Pinealon?
Find a verified provider experienced with Pinealon protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Pinealon ProviderRelated Peptides
Semax
FDA ApprovedA synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotective properties. Semax modulates BDNF and NGF expression, enhances monoaminergic neurotransmission, and provides neuroprotection through anti-oxidant and anti-inflammatory mechanisms. It crosses the blood-brain barrier via intranasal administration.
Selank
InvestigationalA synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stability. Selank exhibits anxiolytic activity comparable to benzodiazepines without sedation, dependence, or withdrawal effects. It modulates the expression of BDNF, serotonin, dopamine, and norepinephrine, and influences IL-6 and GABA receptor expression.
Cerebrolysin
InvestigationalA porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that mimic the action of endogenous neurotrophic factors. Cerebrolysin exhibits neurotrophic activity similar to BDNF, GDNF, and CNTF, promoting neuronal survival, synaptic plasticity, and neurogenesis. It modulates GSK-3beta, CDK5, and calcineurin-NFAT signaling cascades involved in neurodegeneration.
P21 (Peptide)
Research PhaseA small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neurogenesis and synaptic plasticity. P21 is a tetrapeptide that crosses the blood-brain barrier and enhances dentate gyrus neurogenesis by increasing BDNF expression. Unlike full-length CNTF, P21 does not activate the JAK-STAT pathway or produce the anorectic and immunogenic effects of the parent protein.